ATx Electroporator to Design Gene Editing Tools

The National Heart Lung and Blood Institute, part of the National Institutes of Health within the Department of Health and Human Services, has issued a Special Notice for an ATx Electroporator to Design Gene Editing Tools for In Vivo Gene Therapy. This procurement opportunity falls under the Research and Development in Biotechnology category and specifically targets Laboratory Equipment and Supplies. The notice was posted on September 15, 2025, indicating the agency's immediate need for specialized gene editing equipment. This civilian agency procurement represents a focused effort to acquire advanced biotechnology tools for therapeutic research applications. The opportunity does not utilize any set-aside provisions, making it open to all qualified contractors regardless of business size or classification.

The primary objective of this Special Notice is to procure electroporator equipment specifically designed for developing gene editing tools that can be used in live organism gene therapy applications. Contractors interested in responding to this opportunity have a very limited window, as responses are due by September 18, 2025, providing only three days from the posting date. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology, indicating that eligible contractors should have demonstrated expertise in biotechnology research and development services. The PSC category 6640 for Laboratory Equipment and Supplies suggests the agency is seeking both the physical electroporator equipment and potentially associated supplies or services. Given the specialized nature of gene editing tools for in vivo therapy, contractors will likely need to demonstrate advanced technical capabilities in biotechnology equipment design and gene therapy applications. The compressed timeline suggests this may be part of an urgent research initiative requiring immediate procurement action.